Rani Therapeutics | 8-K: FY2025 Q3 Revenue Meets Estimate at USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0, meeting the estimate of USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.12, beating the estimate of USD -0.1233.

EBIT: As of FY2025 Q3, the actual value is USD -6.6 M.

Cash and Cash Equivalents

• As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $4.1 million, compared to $27.6 million as of December 31, 2024. Rani Therapeutics expects its cash, including funds from the private placement and the Chugai agreement, to be sufficient to fund operations into 2028.

Research and Development Expenses

• For the three months ended September 30, 2025, research and development expenses were $3.2 million, a decrease from $6.2 million for the same period in 2024. The reduction was primarily due to lower compensation costs and decreased expenses related to facilities, materials, supplies, and third-party services.

General and Administrative Expenses

• General and administrative expenses for the three months ended September 30, 2025 were $4.0 million, down from $5.6 million for the same period in 2024. This decrease was mainly due to reduced compensation costs and third-party services.

Net Loss

• The net loss for the three months ended September 30, 2025 was $7.9 million, compared to $12.7 million for the same period in 2024. Stock-based compensation expense was $2.3 million for the three months ended September 30, 2025, compared to $4.1 million for the same period in 2024.

Outlook / Guidance

• Rani Therapeutics anticipates initiating a Phase 1 clinical trial for RT-114, a novel oral therapy targeting obesity, by the end of 2025. The trial will assess safety, tolerability, and pharmacokinetics, setting the stage for future development phases.